Enzo named senior party in patent case

By Elaine Rigoli

Tampa, Fla., Aug. 23 - Enzo Biochem, Inc. said Wednesday that the U.S. Patent and Trademark Office has declared two patent interferences designating an allowable Enzo Life Sciences patent application against patents held by Chiron Diagnostics and Princeton University for nucleic acid detection.

The company said Bayer Healthcare LLC, of Tarrytown, N.Y., is the real party in interest to Chiron's patent, and Enzo Life Sciences is the senior party in both interferences.

This nucleic acid technology is the basis for several significant products in clinical diagnostics and in the life-sciences field, which are currently marketed or licensed by various commercial companies.

According to trade reports, industry-wide annual sales of diagnostic products using this technology are estimated to exceed $100 million in the United States alone.

Farmingdale, N.Y.-based Enzo develops health care products based on molecular biology and genetic engineering techniques.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.